Arcoma AB (ARCOMA) - Net Assets

Latest as of September 2025: Skr73.39 Million SEK ≈ $7.90 Million USD

Based on the latest financial reports, Arcoma AB (ARCOMA) has net assets worth Skr73.39 Million SEK (≈ $7.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr97.97 Million ≈ $10.54 Million USD) and total liabilities (Skr24.58 Million ≈ $2.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ARCOMA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr73.39 Million
% of Total Assets 74.91%
Annual Growth Rate 7.78%
5-Year Change 19.79%
10-Year Change 18.87%
Growth Volatility 67.35

Arcoma AB - Net Assets Trend (2012–2024)

This chart illustrates how Arcoma AB's net assets have evolved over time, based on quarterly financial data. See Arcoma AB (ARCOMA) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Arcoma AB (2012–2024)

The table below shows the annual net assets of Arcoma AB from 2012 to 2024. For live valuation and market cap data, see ARCOMA company net worth.

Year Net Assets Change
2024-12-31 Skr59.33 Million
≈ $6.39 Million		 +21.94%
2023-12-31 Skr48.66 Million
≈ $5.24 Million		 +6.06%
2022-12-31 Skr45.88 Million
≈ $4.94 Million		 +4.17%
2021-12-31 Skr44.04 Million
≈ $4.74 Million		 -11.09%
2020-12-31 Skr49.53 Million
≈ $5.33 Million		 +9.62%
2019-12-31 Skr45.19 Million
≈ $4.86 Million		 +15.76%
2018-12-31 Skr39.03 Million
≈ $4.20 Million		 -4.41%
2017-12-31 Skr40.83 Million
≈ $4.39 Million		 +9.33%
2016-12-31 Skr37.35 Million
≈ $4.02 Million		 -25.18%
2015-12-31 Skr49.92 Million
≈ $5.37 Million		 +19.62%
2014-12-31 Skr41.73 Million
≈ $4.49 Million		 +233.32%
2013-12-31 Skr12.52 Million
≈ $1.35 Million		 -48.15%
2012-12-31 Skr24.14 Million
≈ $2.60 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Arcoma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 116.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Skr32.96 Million 55.55%
Common Stock Skr26.37 Million 44.45%
Other Comprehensive Income Skr29.22 Million 49.24%
Total Equity Skr59.33 Million 100.00%

Arcoma AB Competitors by Market Cap

The table below lists competitors of Arcoma AB ranked by their market capitalization.

Company Market Cap
Miwon Chemical
KO:134380
 $13.61 Million
CMX GOLD+SILVER CORP.
F:6GS
 $13.61 Million
Ecoscience International Berhad
KLSE:0255
 $13.62 Million
Kps AG
XETRA:KSC
 $13.62 Million
FIPP S.A.
PA:FIPP
 $13.61 Million
Fang Holdings Ltd
NYSE:SFUNY
 $13.60 Million
Greentech Metals Ltd
AU:GRE
 $13.60 Million
PROBIOTIX HEALTH LS-05
F:X90
 $13.59 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arcoma AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 48,657,000 to 59,334,000, a change of 10,677,000 (21.9%).
  • Net income of 11,179,000 contributed positively to equity growth.
  • Other comprehensive income increased equity by 10,677,001.
  • Other factors decreased equity by 11,179,001.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr11.18 Million +18.84%
Other Comprehensive Income Skr10.68 Million +17.99%
Other Changes Skr-11.18 Million -18.84%
Total Change Skr- 21.94%

Book Value vs Market Value Analysis

This analysis compares Arcoma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.96x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 31.74x to 1.96x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 Skr0.28 Skr8.84 x
2013-12-31 Skr0.14 Skr8.84 x
2014-12-31 Skr0.86 Skr8.84 x
2015-12-31 Skr4.80 Skr8.84 x
2016-12-31 Skr3.61 Skr8.84 x
2017-12-31 Skr3.50 Skr8.84 x
2018-12-31 Skr3.09 Skr8.84 x
2019-12-31 Skr3.57 Skr8.84 x
2020-12-31 Skr3.89 Skr8.84 x
2021-12-31 Skr3.40 Skr8.84 x
2022-12-31 Skr3.51 Skr8.84 x
2023-12-31 Skr3.65 Skr8.84 x
2024-12-31 Skr4.50 Skr8.84 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arcoma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 18.84%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.13%
  • • Asset Turnover: 1.95x
  • • Equity Multiplier: 1.36x
  • Recent ROE (18.84%) is above the historical average (-11.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 -13.36% -2.19% 2.16x 2.84x Skr-5.64 Million
2013 -92.85% -11.47% 1.43x 5.66x Skr-12.88 Million
2014 2.19% 0.70% 1.65x 1.90x Skr-3.26 Million
2015 -12.92% -5.23% 1.46x 1.69x Skr-11.44 Million
2016 -31.18% -11.41% 1.43x 1.91x Skr-15.38 Million
2017 -24.05% -10.69% 1.35x 1.67x Skr-13.90 Million
2018 -4.06% -1.33% 1.57x 1.95x Skr-5.49 Million
2019 14.63% 4.94% 1.60x 1.84x Skr2.09 Million
2020 2.76% 1.16% 1.24x 1.92x Skr-3.59 Million
2021 -16.97% -6.38% 1.48x 1.80x Skr-11.88 Million
2022 4.15% 1.52% 1.25x 2.19x Skr-2.69 Million
2023 5.27% 1.57% 1.99x 1.68x Skr-2.30 Million
2024 18.84% 7.13% 1.95x 1.36x Skr5.25 Million

Industry Comparison

This section compares Arcoma AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $166,575,685
  • Average return on equity (ROE) among peers: -66.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Arcoma AB (ARCOMA) Skr73.39 Million -13.36% 0.33x $13.61 Million
Acarix A/S (ACARIX) $100.54 Million -51.52% 0.18x $31.21 Million
Bactiguard Holding AB (publ) (BACTI-B) $387.11 Million -0.84% 0.62x $54.96 Million
BICO Group AB (BICO) $549.64 Million 0.11% 0.10x $124.14 Million
Boule Diagnostics AB (BOUL) $192.86 Million 6.07% 0.41x $13.37 Million
CellaVision AB (CEVI) $206.18 Million 29.00% 0.24x $351.14 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $3.68 Million -18.24% 0.50x $11.99 Million
Chordate Medical Holding AB (CMH) $15.09 Million -193.46% 0.46x $29.05K
C-Rad AB (publ) (CRAD-B) $38.03 Million -55.21% 0.62x $127.56 Million
Duearity AB (DEAR) $6.06 Million -318.56% 0.99x $331.97K

About Arcoma AB

ST:ARCOMA Sweden Medical Devices
Market Cap
$13.61 Million
Skr126.49 Million SEK
Market Cap Rank
#26270 Global
#558 in Sweden
Share Price
Skr8.84
Change (1 day)
-6.55%
52-Week Range
Skr6.92 - Skr10.75
All Time High
Skr25.60
Categories
Companies in Sweden Medical Devices
About

Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanc… Read more